Floatz logo

Therapeutic Asset Ratings

6,308 results matching 1 filter

91,564 assets7,904 sponsors3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102
Anal Carcinoma
Oncolytics BiotechP1/2CCC (48)
Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102
Anal Squamous Cell Carcinoma
Oncolytics BiotechP1/2CCC (48)
Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102
Exocrine Pancreatic Carcinoma
Oncolytics BiotechP1/2CCC (48)
Trospium
Schizoaffective Disorder
New York State Psychiatric InstituteP1/2CCC (48)
trx103
Crohn Disease
Tr1X, Inc.P1/2CCC (48)
trx319
Secondary Progressive Multiple Sclerosis
Tr1X, Inc.P1/2CCC (48)
Tsha-105
Developmental And Epileptic Encephalopathy, 25
TESS Research FoundationP1/2CCC (48)
Tsra-196
Alpha 1-Antitrypsin Deficiency
Tessera Therapeutics, Inc.P1/2CCC (48)
Tucatinib
Central Nervous System Disorder
Reva BashoP1/2CCC (48)
Tucidinostat
Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma
Sun Yat-sen UniversityP1/2CCC (48)
Tucidinostat
Disease Related To Hematopoietic Stem Cell Transplant
Chinese PLA General HospitalP1/2CCC (48)
Tuspetinib
Myelodysplastic Syndrome With Excess Blasts-2
Aptose Biosciences Inc.P1/2CCC (48)
Tuvusertib
Colorectal Carcinoma
National Cancer Institute (NCI)P1/2CCC (48)
Tuvusertib
Metastatic Malignant Neoplasm
National Cancer Institute (NCI)P1/2CCC (48)
Tuvusertib
Colorectal Cancer
National Cancer Institute (NCI)P1/2CCC (48)
ty-1091
Medullary Thyroid Gland Carcinoma
TYK Medicines, IncP1/2CCC (48)
ty-1091
Non-Small Cell Lung Carcinoma
TYK Medicines, IncP1/2CCC (48)
ty-1091
Thyroid Gland Papillary Carcinoma
TYK Medicines, IncP1/2CCC (48)
Tyra-300
Urothelial Carcinoma
Tyra Biosciences, IncP1/2CCC (48)
Tyra-300
Superficial Urinary Bladder Carcinoma
Tyra Biosciences, IncP1/2CCC (48)
Tyra-300
Urinary System Neoplasm
Tyra Biosciences, IncP1/2CCC (48)
u32 car-t
Acute Myeloid Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdP1/2CCC (48)
Ubamatamab
Ovarian Serous Adenocarcinoma
Regeneron PharmaceuticalsP1/2CCC (48)
Ubamatamab
Endometrial Cancer
Regeneron PharmaceuticalsP1/2CCC (48)
Ublituximab
B-Cell Non-Hodgkin Lymphoma
Yazeed SawalhaP1/2CCC (48)
Showing 1976 to 2000 of 6,308 assets
PreviousPage 80 of 253Next